

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED


JUL 19 2002

TECH CENTER 1600/2900

In re the application of: Michael J. Marzulli

Serial No.: 09/643,260

Filed: August 22, 2000



Group Art Unit: 1653

Examiner: Mitra, Rita

For: *INHIBITION OF NF- κ B ACTIVATION BY
BLOCKADE OF IKK β -NEMO INTERACTIONS AT THE
NEMO BINDING DOMAIN*

Attorney Docket No.: PPI-117

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

July 10, 2002
Date of Signature and of Mail Deposit

By:

Maria C. Laccotripe, Ph.D.
Limited Recognition Under 37 C.F.R. §10.9(b)
Attorney for Applicant

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the Office Action dated June 10, 2002 (Paper No. 7) setting forth a restriction requirement.

The Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

I. Claims 1-5, drawn to a method of inhibiting NF- κ B induction in a cell by administering a peptide which blocks the interaction of one or more IKKs and NEMO, classified in class 514, subclass 2.

Should Group I be elected, applicants are required to select one sequence of peptides of SEQ ID NOs: 2, 4-6, 11-12, 16-17.